TSPAN7 and plasma cell myeloma: TSPAN7 significantly reduced tumor burden in 5TGM1/KaLwRij mice 4 weeks after intravenous injection of the murine myeloma cell line 5TGM1 by increasing cell adhesion to stromal cells and transendothelial migration, with no impact on cell proliferation [74].